Skip to content
Screener

Total Liabilities at other companies

LON
LeonaBio, Inc.LONA
$22.29M+260%
Oric Pharmaceuticals, Inc. logo
Oric Pharmaceuticals, Inc.ORIC
$21.21M-8.3%
Opko Health logo
Opko HealthOPK
$645.29M-4.6%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
$48.4M-14.8%
IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
$93.08M+21.7%
Erasca, Inc. logo
Erasca, Inc.ERAS
$67.71M-5.6%

Other financials

Income statement

See full
Operating income-$58.0M-66.3%
Net income-$53.1M-74.7%
EPS (diluted)-$0.52-44.4%

Balance sheet

See full
Cash & equivalents$52.5M+3.8%
Total debt$956.0K-16.7%
Total equity$480.5M+25.3%
Total assets$530.6M+29.5%

Cash flow

See full
Operating cash flow-$46.0M-4.6%
CapEx-
Free cash flow-$34.5M-27.8%

Valuation

See full
Market cap$1.03B+202%
Enterprise value$979.11M+238%

Returns & leverage

See full
Return on equity-42.9%+1.3pp
Debt / equity0.0×
Current ratio10.9×-4.3×

Where this comes from

Reported directly by Olema Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:Liabilities.

The source filing: Olema Pharmaceuticals, Inc.’s 10-Q, filed May 12, 2026.

Filed
May 12, 2026, 7:10 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-218156
Line itemMarch 31, 2026December 31, 2025
Non-current liabilities:
Operating lease liabilities, net of current portion69
Long-term borrowing3,0003,000
Total liabilities50,16754,871
Commitments and contingencies (Note 10)
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of March 31, 2026 and December 31, 2025; no shares issued and outstanding as of March 31, 2026 and December 31, 2025.
Common stock, $0.0001 par value; 490,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 87,332,971 and 81,376,449 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively.88

Item 1. Financial Statements.

FAQ

What is Olema Pharmaceuticals, Inc.'s total liabilities?
Olema Pharmaceuticals, Inc. (OLMA) reported total liabilities of $50.17M in Q1 2026.
How has Olema Pharmaceuticals, Inc.'s total liabilities changed year-over-year?
Olema Pharmaceuticals, Inc.'s total liabilities increased by 91.6% year-over-year, from $26.19M to $50.17M.
What is the long-term trend for Olema Pharmaceuticals, Inc.'s total liabilities?
Over 5 years (2020 to 2025), Olema Pharmaceuticals, Inc.'s total liabilities has grown at a 64.3% compound annual growth rate (CAGR), from $4.59M to $54.87M.
What does total liabilities mean?
The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.

Ask your AI about Olema Pharmaceuticals, Inc.'s total liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude